SOD1 and heavy chain disease: Both the doses of LT treatment markedly enhanced SOD activities in cardiac (P < 0.05 and P < 0.001; respectively), hepatic (P < 0.05 and P < 0.01; respectively) and renal (P < 0.05) tissues compared to HCD group.